Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sabine Furst

Showing results (11-20 of 49) with videos related to

Pageof 5
Sort By:
Experimental Hematology|October 20, 2009
Platelet recovery and transfusion needs after reduced intensity conditioning allogeneic peripheral blood stem cell transplantationThomas Prébet, Patrick Ladaique, Martin Ferrando, et al.
Cancer|October 7, 2014
Reduced-toxicity conditioning with fludarabine, once-daily intravenous busulfan, and antithymocyte globulins prior to allogeneic stem cell transplantation: results of a multicenter prospective phase 2 trialMohamad Mohty, Florent Malard, Didier Blaise, et al.
Bone Marrow Transplantation|March 11, 2018
Cost-effectiveness analysis of haploidentical vs matched unrelated allogeneic hematopoietic stem cells transplantation in patients older than 55 yearsMathias Debals-Gonthier, Carole Siani, Catherine Faucher, et al.
Haematologica|August 3, 2014
Reduced-toxicity conditioning prior to allogeneic stem cell transplantation improves outcome in patients with myeloid malignanciesClaire Oudin, Patrice Chevallier, Sabine Furst, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 4, 2017
T Cell-Replete Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for Hodgkin Lymphoma Relapsed after Autologous Transplantation: Reduced Incidence of Relapse and of Chronic Graft-versus-Host Disease Compared with HLA-Identical Related DonorsJacopo Mariotti, Raynier Devillier, Stefania Bramanti, et al.
Experimental Hematology|October 2, 2012
Donor CD3(+) lymphocyte infusion after reduced intensity conditioning allogeneic stem cell transplantation: single-center experienceJean El-Cheikh, Roberto Crocchiolo, Sabine Furst, et al.
Bone Marrow Transplantation|January 26, 2019
The new refined minnesota risk score for acute graft-versus-host disease predicts overall survival and non-relapse mortality after T cell-replete haploidentical stem cell transplant with post-transplant cyclophosphamideJacopo Mariotti, Angela Granata, Stefania Bramanti, et al.
Leukemia & Lymphoma|February 18, 2016
The efficacy and safety of a new reduced-toxicity conditioning with 4 days of once-daily 100 mg/m(2) intravenous busulfan associated with fludarabine and antithymocyte globulins prior to allogeneic stem cell transplantation in patients with high-risk myelodysplastic syndrome or acute leukemiaAnne Wanquet, Roberto Crocchiolo, Sabine Furst, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 18, 2014
Bone marrow compared with peripheral blood stem cells for haploidentical transplantation with a nonmyeloablative conditioning regimen and post-transplantation cyclophosphamideLuca Castagna, Roberto Crocchiolo, Sabine Furst, et al.
Bulletin Du Cancer|January 11, 2021
[Eligibility of patients for CAR T-cell: Expert opinion-based collaborative work by the SFGM-TC]David Beauvais, Emmanuel Bachy, André Baruchel, et al.
Pageof 5

Showing results (11-20 of 49) with videos related to

Sort By:
Pageof 5
Experimental Hematology|October 20, 2009
Platelet recovery and transfusion needs after reduced intensity conditioning allogeneic peripheral blood stem cell transplantationThomas Prébet, Patrick Ladaique, Martin Ferrando, et al.
Cancer|October 7, 2014
Reduced-toxicity conditioning with fludarabine, once-daily intravenous busulfan, and antithymocyte globulins prior to allogeneic stem cell transplantation: results of a multicenter prospective phase 2 trialMohamad Mohty, Florent Malard, Didier Blaise, et al.
Bone Marrow Transplantation|March 11, 2018
Cost-effectiveness analysis of haploidentical vs matched unrelated allogeneic hematopoietic stem cells transplantation in patients older than 55 yearsMathias Debals-Gonthier, Carole Siani, Catherine Faucher, et al.
Haematologica|August 3, 2014
Reduced-toxicity conditioning prior to allogeneic stem cell transplantation improves outcome in patients with myeloid malignanciesClaire Oudin, Patrice Chevallier, Sabine Furst, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 4, 2017
T Cell-Replete Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for Hodgkin Lymphoma Relapsed after Autologous Transplantation: Reduced Incidence of Relapse and of Chronic Graft-versus-Host Disease Compared with HLA-Identical Related DonorsJacopo Mariotti, Raynier Devillier, Stefania Bramanti, et al.
Experimental Hematology|October 2, 2012
Donor CD3(+) lymphocyte infusion after reduced intensity conditioning allogeneic stem cell transplantation: single-center experienceJean El-Cheikh, Roberto Crocchiolo, Sabine Furst, et al.
Bone Marrow Transplantation|January 26, 2019
The new refined minnesota risk score for acute graft-versus-host disease predicts overall survival and non-relapse mortality after T cell-replete haploidentical stem cell transplant with post-transplant cyclophosphamideJacopo Mariotti, Angela Granata, Stefania Bramanti, et al.
Leukemia & Lymphoma|February 18, 2016
The efficacy and safety of a new reduced-toxicity conditioning with 4 days of once-daily 100 mg/m(2) intravenous busulfan associated with fludarabine and antithymocyte globulins prior to allogeneic stem cell transplantation in patients with high-risk myelodysplastic syndrome or acute leukemiaAnne Wanquet, Roberto Crocchiolo, Sabine Furst, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 18, 2014
Bone marrow compared with peripheral blood stem cells for haploidentical transplantation with a nonmyeloablative conditioning regimen and post-transplantation cyclophosphamideLuca Castagna, Roberto Crocchiolo, Sabine Furst, et al.
Bulletin Du Cancer|January 11, 2021
[Eligibility of patients for CAR T-cell: Expert opinion-based collaborative work by the SFGM-TC]David Beauvais, Emmanuel Bachy, André Baruchel, et al.
Pageof 5